Assessing Radiological Response to Immunotherapy in Lung Cancer: An Evolving Arena

Area of Science:

• Oncology
• Radiology
• Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized non-small-cell lung cancer (NSCLC) treatment, offering survival benefits for advanced and metastatic disease.
• The efficacy of ICIs is particularly notable in patients with non-targetable genetic oncogenic driver mutations.
• However, unique challenges have emerged, including atypical immunotherapy response patterns and immune-related adverse events.

Purpose of the Study:

• To review and discuss response evaluation criteria tailored for immunotherapy in NSCLC.
• To address the need for improved methods to characterize radiological findings specific to immunotherapy response.
• To enhance the accuracy of patient response classification in the context of novel immune-based treatments.

Main Methods:

• Literature review focusing on response evaluation criteria for immunotherapy in NSCLC.
• Analysis of unique radiological findings associated with immunotherapy.
• Discussion of modified RECIST (Response Evaluation Criteria for Solid Tumors) criteria and emerging assessment methods.

Main Results:

• Traditional RECIST criteria may not fully capture the nuances of immunotherapy response in NSCLC.
• Atypical response patterns such as pseudo-progression and hyperprogressive disease require specialized evaluation.
• Newer versions of RECIST and other criteria aim to better characterize radiological changes indicative of treatment efficacy or toxicity.

Conclusions:

• Accurate radiological assessment is crucial for optimizing immunotherapy in NSCLC.
• Adaptation of response evaluation criteria is necessary to account for immunotherapy's unique effects on tumor imaging.
• Further refinement of criteria will improve patient management and treatment outcomes in the era of immune-based therapies.